x
Filter:
Filters applied
- Opioids
- Raja, Srinivasa NRemove Raja, Srinivasa N filter
Author
- Gourlay, Geoffrey K2
- Haanpää, Maija L2
- Kent, Joel L2
- Miaskowski, Christine2
- Schmader, Kenneth E2
- Wells, Christopher D2
- Audette, Joseph1
- Baron, Ralf1
- Dworkin, Robert H1
- Krane, Elliot J1
- LeBel, Alyssa A1
- Levy, Robert M1
- Mackey, Sean C1
- Mayer, John1
- O'Connor, Alec B1
- Rice, Andrew SC1
- Stacey, Brett1
- Stanos, Steven1
- Treede, Rolf-Detlef1
- Turk, Dennis C1
- Walco, Gary A1
Opioids
2 Results
- SUPPLEMENT ARTICLE
Treatment Considerations for Patients With Neuropathic Pain and Other Medical Comorbidities
Mayo Clinic ProceedingsVol. 85Issue 3SupplementS15–S25Published in issue: March, 2010- Maija L. Haanpää
- Geoffrey K. Gourlay
- Joel L. Kent
- Christine Miaskowski
- Srinivasa N. Raja
- Kenneth E. Schmader
- and others
Cited in Scopus: 72The efficacy of drugs for neuropathic pain has been established in randomized controlled trials that have excluded patients with comorbid conditions and those taking complex medications. However, patients with neuropathic pain frequently present with complex histories, making direct application of this evidence problematic. Treatment of neuropathic pain needs to be individualized according to the cause of the pain, concomitant diseases, medications, and other individual factors. Tricyclic antidepressants (TCAs), gabapentinoids, selective noradrenergic reuptake inhibitors, and topical lidocaine are the first-line choices; if needed, combination therapy may be used. - SUPPLEMENT ARTICLE
Recommendations for the Pharmacological Management of Neuropathic Pain: An Overview and Literature Update
Mayo Clinic ProceedingsVol. 85Issue 3SupplementS3–S14Published in issue: March, 2010- Robert H. Dworkin
- Alec B. O'Connor
- Joseph Audette
- Ralf Baron
- Geoffrey K. Gourlay
- Maija L. Haanpää
- and others
Cited in Scopus: 1023The Neuropathic Pain Special Interest Group of the International Association for the Study of Pain recently sponsored the development of evidence-based guidelines for the pharmacological treatment of neuropathic pain. Tricyclic antidepressants, dual reuptake inhibitors of serotonin and norepinephrine, calcium channel α2-δ ligands (ie, gabapentin and pregabalin), and topical lidocaine were recommended as first-line treatment options on the basis of the results of randomized clinical trials. Opioid analgesics and tramadol were recommended as second-line treatments that can be considered for first-line use in certain clinical circumstances.
